FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer ...
FDA approves Roche’s Tecentriq Hybreza, the first subcutaneous anti-PD-(L) cancer immunotherapy, offering greater treatment flexibility with consistent safety and efficacy.
Highlighted Terms
Related News
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer ...
FDA approves Roche’s Tecentriq Hybreza, the first subcutaneous anti-PD-(L) cancer immunotherapy, offering greater treatment flexibility with consistent safety and efficacy.